Who is sponsoring NCT05309694?

NCT05309694 is sponsored by CooperSurgical Inc..

What drugs are being tested in NCT05309694?

Interventions in NCT05309694: Paragard® T380A Intrauterine Copper Contraceptive with New Inserter.

What condition does NCT05309694 study?

NCT05309694 studies Contraception.

Is NCT05309694 still recruiting?

NCT05309694 is currently completed. Last updated 20 January 2023.

Last reviewed 2023-01-20 · How we verify

NCT05309694

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Safety of a New Inserter Device for Paragard® (Intrauterine Copper Contraceptive)

Completed Phase 4 Last updated 20 January 2023

What this trial tests

Phase 4 trial testing Paragard® T380A Intrauterine Copper Contraceptive with New Inserter in Contraception in 119 participants. Completed in 8 December 2022.

Timeline

4 March 2022

Primary endpoint
8 December 2022

8 December 2022

Quick facts

Lead sponsor	CooperSurgical Inc.
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	119
Start date	4 March 2022
Primary completion	8 December 2022
Estimated completion	8 December 2022
Sites	8 locations across United States

Drugs / interventions tested

Paragard® T380A Intrauterine Copper Contraceptive with New Inserter

Conditions studied

Contraception — all drugs for Contraception →

Sponsor

CooperSurgical Inc.

Who can join

18 and older, female only, with Contraception. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to demonstrate that a new device inserter leads to successful and safe insertion of Paragard® IUS, comparable to the currently approved IUS inserter, in females of reproductive potential.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Placement of the T380A Intrauterine Copper Contraceptive Using a Single-Hand Inserter.
Dunsmoor-Su RF, Desai VB, Pandolfi EC, Audette CR, et al · · 2025 · PMID 41000288 · DOI 10.1097/og9.0000000000000068

Verify or expand the search:

Other recruiting trials for Contraception

Currently open trials in the same condition.

NCT07365904 — Investigating Ovulation Inhibition for Use as a Contraceptive · Phase 2 · recruiting
NCT07437495 — Women's Knowledge of Contraception During the Postpartum Period · active not recruiting
NCT06823037 — Hormonal Contraception Access Through Pharmacist Prescribing Implementation · NA · recruiting
NCT07326007 — Verbal Analgesia Versus Standard Technique for Pain Control During Copper T380A Intrauterine Device Insertion in Women W · NA · recruiting
NCT05910580 — Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05309694 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CooperSurgical Inc.
Last refreshed: 20 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05309694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing